Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ceritinib + hALK.CAR T cells |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ceritinib | Zykadia | LDK378 | ALK Inhibitor 33 ROS1 Inhibitor 22 | Zykadia (ceritinib) inhibits ALK, including ALK mutations and fusions, and has additional activity against ROS1 fusions, potentially resulting in decreased tumor cell growth (PMID: 25322323, PMID: 26372962). Zykadia (ceritinib) is FDA approved for ALK-positive (rearrangements and fusions) metastatic non-small cell lung cancer (FDA.gov). |
hALK.CAR T cells | hALK.CAR T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting ALK linked to the CD8 alpha hinge and transmembrane domain, CD28 costimulatory domain, and CD3zeta signaling domain, which potentially induces cytoxicity against tumor cells with high Alk expression (PMID: 38039964). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK R1275Q | neuroblastoma | sensitive | Ceritinib + hALK.CAR T cells | Preclinical - Cell culture | Actionable | In a preclinical study, Zykadia (ceritinib) treatment resulted in increased death of neuroblastoma cells harboring ALK R1275Q when co-cultured with hALK.CAR T cells compared to control CAR-T cells in culture (PMID: 38039964). | 38039964 |
ALK F1174L | neuroblastoma | sensitive | Ceritinib + hALK.CAR T cells | Preclinical - Cell culture | Actionable | In a preclinical study, Zykadia (ceritinib) treatment resulted in increased death of neuroblastoma cells harboring ALK F1174L when co-cultured with hALK.CAR T cells compared to control CAR-T cells in culture (PMID: 38039964). | 38039964 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|